Table 1.
Baseline characteristics of the recipients.
| All (n = 100) | Living (n = 56) | Deceased (n = 44) | p-value | |
|---|---|---|---|---|
| Age (years, mean ± SD) | 49.31 (15.62) | 42.76 (15.06) | 57.65 (12.02) | 0.000a |
| Male, n (%) | 64 (64) | 35 (62.5) | 29 (65.9) | 0.728a |
| Diagnosis of ESRD, n (%) | 0.498b | |||
| Hypertension | 13 (13) | 7 (12.5) | 6 (13.6) | |
| Diabetes | 3 (3) | 0 (0) | 3 (6.8) | |
| Polycystic kidney disease | 13 (13) | 6 (10.7) | 7 (15.9) | |
| Obstructive nephropathy | 4 (4) | 3 (5.3) | 1 (2.3) | |
| Glomerulonephritis | 33 (33) | 21 (37.5) | 12 (27.3) | |
| FSGS | 7 (7) | 5 (8.9) | 2 (4.5) | |
| Interstitial nephritis | 3 (3) | 1 (1,8) | 2 (4.5) | |
| Vasculitis | 2 (2) | 2 (3.6) | 0 (0) | |
| Other | 22 (22) | 11 (19.6) | 11 (25) | |
| Mode of dialysis, n (%) | 0.009b | |||
| Hemodialysis | 71 (71) | 40 (71.4) | 31 (70.4) | |
| Peritoneal dialysis | 12 (12) | 6 (10.7) | 6 (13.6) | |
| Both | 9 (9) | 2 (3.6) | 7 (16) | |
| Preemptive donation | 8 (8) | 8 (14.3) | 0 (0) | |
| Time on dialysis (months, mean (1st & 3rd quartile)) | 44.9 (11.3, 79.2) | 19.7 (0.9, 26.2) | 77.5 (41.6, 102.2) | 0.000c |
| Immunized | 38 (38) | 21 (37.5) | 17 (39) | 0.907d |
| European senior program (ESP) | 14 (14) | 0 (0) | 14 (32) | 0.000d |
| ≥ 1 prior kidney transplantat, n (%) | 14 (14) | 8 (14.3) | 6 (13.6) | 0.926d |
| Current PRA, n (%) | 0.567b | |||
| 0–20% | 73 (73) | 41 (73.2) | 32 (73) | |
| > 20% | 27 (73) | 15 (26.8) | 12 (27.3) | |
| Induction, n (%) | 0.000b | |||
| Basiliximab | 75 (75) | 38 (67.8) | 37 (84.1) | |
| Thymoglobuline | 5 (5) | 0 (0) | 5 (11.3) | |
| Basiliximab + Thymoglobuline | 1 (1) | 0 (0) | 1 (2.3) | |
| Rituximab + Thymoglobuline | 1 (1) | 1 (1.8) | 0 (0) | |
| Rituximab + Basiliximab | 16 (16) | 16 (28.6) | 0 (0) | |
| Eculizumab + Basiliximab | 2 (2) | 1 (2.6) | 1 (2.3) | |
| Cold ischemia time (hours, mean ± SD) | 5.77 (7.8) | 2.47 (0.64) | 9.96 (3.3) | 0.000a |
| Warm ischemia time (min, mean ± SD) | 34.3 (4.35) | 33.46 (8.03) | 35.4 (7.36) | 0.211a |
| AB0i | 17 (17) | 17 (30.4%) | 0 (0) | 0.000b |
| eGFR 365 days (ml/min/1.73 m2, mean ± SD) | 57.32 (20.06) | 60.01 (20.25) | 53.9 (19.5) | 0.131a |
Demographic characteristics of the study population. The results have been presented as mean ± standard deviation or median and 1st and 3rd quartile, respectively, or as absolute and relative frequencies.
ESRD end-stage renal disease, FSGS focal segmental glomerulosclerosis, ESP European Senior Program, HLA human leukocyte antigen, PRA panel reactive antibodies, eGFR estimated glomerular filtration rate, SD standard deviation.
aMann–Whitney U test.
bFisher’s exact test.
cKruskal–Wallis test.